Drugs / BMS-929075
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01525212 | Apr 2012 → Feb 2013 | chronic hepatitis C virus infection | Bristol-Myers Squibb | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-929075 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01525212 ↗ |
| Modality | Small molecule | — CHEMBL4093031 ↗ |
| Route | Oral | “Oral Suspension” NCT01525212 ↗ |